HCC treatment
Continue their journey for as long as possible with Nexavar® (sorafenib) then Stivarga® (regorafenib)
Over the past decade, first-line Nexavar has established itself as the standard of care for patients with unresectable HCC by offering increased median overall survival (OS) vs. placebo. Stivarga is the only second-line treatment to be recommended by NICE and accepted for use by the SMC for patients with advanced or metastatic HCC who have tolerated and progressed on Nexavar.
Nexavar then Stivarga, in sequence, have the potential to improve outcomes in your HCC patients (vs Nexavar then placebo) and help you to continue what you started.
Discover how you can learn about survival benefit of your patients with HCC while potentially optimising quality of life by clicking on the relevant treatment goal below.
Nexavar is indicated for the treatment of adult patients with HCC while Stivarga is indicated for the treatment of adult patients with HCC who have been previously treated with Nexavar.
Which aspect of treatment are you interested in?
Mechanism of action
Nexavar is a multikinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro
Abbreviations: BRAF: B-Raf proto-oncogene; serine/threonine kinase; CRAF: C-Raf proto oncogene serine/threonine kinase; c-KIT: c-KIT, c-V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; FLT: fms-like tyrosine kinase; PDGFR: platelet-derived growth factor receptor; RET: rearranged during transfection; VEGFR: vascular endothelial growth factor receptor.
PP-NEX-GB-0211 | February 2024
- expand_more